International Stem Cell Corp. (ISCO)

[Doctor_Hari_Seldon]

Yes. I liked it because it provides succinct detail in about as concise manner as possible, which is what a good abstract should. They hit basically everything in it, including detail often glossed over in press releases. It provides trial numbers, trial periods, patient numbers, dosages, observation periods, accurate descriptions of intracranial placements, patient idiopathic values/ranges, patient age group, cell placement technique, regulatory agency information, patient pretrial motor skill rankings, and program funding all in one abstract paragraph.